MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%
Last update at 2024-10-30T18:52:00Z
Possible Bearish Signals With Cencora Insiders Disposing Stock
Fri 18 Oct 24, 11:00 AMWill Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Tue 15 Oct 24, 04:10 PMHere's Why Cencora (COR) is a Strong Growth Stock
Fri 11 Oct 24, 01:45 PMIf EPS Growth Is Important To You, Cencora (NYSE:COR) Presents An Opportunity
Thu 10 Oct 24, 01:00 PMThose who invested in Cencora (NYSE:COR) five years ago are up 193%
Fri 04 Oct 24, 01:00 PMWhy Drug Distributors Are Buying Cancer Specialists
Fri 27 Sep 24, 11:00 AMThese 4 Measures Indicate That Cencora (NYSE:COR) Is Using Debt Reasonably Well
Fri 20 Sep 24, 11:00 AMCencora Insiders Sell US$13m Of Stock, Possibly Signalling Caution
Sat 14 Sep 24, 01:00 PMHere's Why We Think Cencora (NYSE:COR) Might Deserve Your Attention Today
Tue 10 Sep 24, 11:01 AMWhy Walgreens Boots Alliance Fell Another 22% in August
Thu 05 Sep 24, 10:30 AM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 2160.84M | 2183.06M | 2221.86M | -5293.83100M | 967.11M |
| Minority interest | 12.72M | 32.28M | -4.67600M | -9.15800M | 1.23M |
| Net income | 1745.29M | 1698.82M | 1539.93M | -3408.71600M | 855.37M |
| Selling general administrative | 5309.98M | 4848.96M | 3594.25M | 80.57M | 76.39M |
| Selling and marketing expenses | - | - | - | 23.73M | 2663.51M |
| Gross profit | 8959.49M | 8334.57M | 6774.43M | 5195.36M | 5138.31M |
| Reconciled depreciation | 963.90M | 693.89M | 514.79M | 391.06M | 462.41M |
| Ebit | 2734.64M | 2780.86M | 2894.01M | 2035.19M | 2025.35M |
| Ebitda | 3698.55M | 3474.76M | 3408.80M | 2426.25M | 2487.76M |
| Depreciation and amortization | 963.90M | 693.89M | 514.79M | 391.06M | 462.41M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 2340.73M | 2366.38M | 2354.20M | -5135.35400M | 1111.92M |
| Other operating expenses | 259487.81M | 235833.50M | 211145.04M | 187860.32M | 177576.72M |
| Interest expense | 228.93M | 210.67M | 182.54M | 137.88M | 157.77M |
| Tax provision | 428.26M | 516.52M | 677.25M | -1894.27300M | 112.97M |
| Interest income | 228.93M | 21.31M | 8.47M | 20.64M | 37.70M |
| Net interest income | -228.93100M | -210.67300M | -174.07400M | -137.88300M | -157.76900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 428.26M | 516.52M | 677.25M | -1894.27300M | 112.97M |
| Total revenue | 262173.41M | 238587.01M | 213988.84M | 189893.93M | 179589.12M |
| Total operating expenses | 6273.89M | 5542.86M | 4099.42M | 3158.28M | 3125.91M |
| Cost of revenue | 253213.92M | 230252.44M | 207214.41M | 184698.56M | 174450.81M |
| Total other income expense net | -295.83800M | -359.78000M | -447.87200M | -7189.55300M | -887.52200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1732.58M | 1666.54M | 1544.61M | -3399.55800M | 854.13M |
| Net income applicable to common shares | 1745.29M | 1698.82M | 1539.93M | -3408.71600M | 855.37M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 62558.75M | 56560.62M | 57337.81M | 43947.86M | 39171.98M |
| Intangible assets | 14005.90M | 4332.74M | 5256.93M | 1886.11M | 2294.84M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1840.93M | 2192.50M | 2125.16M | 1533.95M | 1310.73M |
| Total liab | 61892.46M | 56489.34M | 56753.39M | 44787.50M | 36178.77M |
| Total stockholder equity | 666.29M | -289.78400M | 223.35M | -839.63600M | 2993.21M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2353.82M | 2214.59M | 192.07M | 1593.61M | 1057.21M |
| Common stock | 666.29M | 2.93M | 2.91M | 2.88M | 2.85M |
| Capital stock | - | 2.93M | 2.91M | 2.88M | 2.85M |
| Retained earnings | - | 2977.65M | 1670.51M | 518.34M | 4235.49M |
| Other liab | - | 7514.74M | 8064.89M | 7257.62M | 2243.08M |
| Good will | - | 8503.89M | 9030.53M | 6706.72M | 6705.51M |
| Other assets | 3618.85M | 1054.26M | 1017.60M | 697.97M | 269.07M |
| Cash | 2592.05M | 3388.19M | 2547.14M | 4597.75M | 3374.19M |
| Cash and equivalents | 2592.05M | 3388.19M | 2547.14M | 4597.75M | - |
| Total current liabilities | 48831.20M | 43477.96M | 41358.64M | 33853.08M | 29581.29M |
| Current deferred revenue | -641.34400M | - | 2856.41M | 53.15M | - |
| Net debt | 2195.41M | 2314.64M | 4136.78M | -478.22600M | 798.70M |
| Short term debt | 641.34M | 1070.47M | 300.21M | 501.26M | 139.01M |
| Short long term debt | 641.34M | 1070.47M | 300.21M | 501.26M | 139.01M |
| Short long term debt total | 4787.46M | 5702.83M | 6683.92M | 4119.52M | 4172.89M |
| Other stockholder equity | 666.29M | -1439.38700M | -1004.62400M | -1252.01900M | -1133.17300M |
| Property plant equipment | 2135.17M | 3079.98M | 3230.14M | 1928.33M | 1770.52M |
| Total current assets | 42798.83M | 39589.76M | 38802.61M | 33019.85M | 28132.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -13048.18200M | -14064.10400M | -9611.75000M | -6121.42600M |
| Short term investments | - | 0.00000M | 372.91M | - | - |
| Net receivables | 20911.08M | 18452.67M | 18389.05M | 14298.88M | 12386.88M |
| Long term debt | 4146.11M | 4632.36M | 6383.71M | 3618.26M | 4033.88M |
| Inventory | 17454.77M | 15556.39M | 15368.35M | 12589.28M | 11060.25M |
| Accounts payable | 45836.04M | 40192.89M | 38009.95M | 31705.06M | 28385.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -1830.97000M | -445.44200M | -108.83000M | -111.96500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3418.18M | 1761.66M | 1793.99M | 779.85M | 269.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 19759.92M | 16970.86M | 18535.20M | 10928.01M | 11039.93M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 4146.11M | 4632.36M | 6383.71M | 3618.26M | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -2602.46500M | -368.43700M | -6141.57700M | -379.87100M | -375.83200M |
| Change to liabilities | - | 3320.72M | 2049.17M | 3300.83M | 1561.05M |
| Total cashflows from investing activities | -2602.46500M | -368.43700M | -6141.57700M | -379.87100M | -375.83200M |
| Net borrowings | - | -923.10300M | 2216.55M | -32.00600M | -133.07300M |
| Total cash from financing activities | -2222.27800M | -1752.78000M | 1952.85M | -603.61700M | -1086.51300M |
| Change to operating activities | - | -854.72000M | 276.14M | 6751.01M | 234.22M |
| Net income | 1732.58M | 1666.54M | 1544.61M | -3399.55800M | 854.13M |
| Change in cash | -840.65000M | 523.41M | -1527.61800M | 1223.55M | 881.68M |
| Begin period cash flow | 3593.54M | 3070.13M | 4597.75M | 3374.19M | 2492.52M |
| End period cash flow | 2752.89M | 3593.54M | 3070.13M | 4597.75M | 3374.19M |
| Total cash from operating activities | 3911.33M | 2703.09M | 2666.59M | 2207.04M | 2344.02M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 66.36M | - |
| Depreciation | 963.90M | 709.84M | 514.79M | 408.01M | 497.51M |
| Other cashflows from investing activities | -2144.10600M | 127.88M | -5703.36000M | -10.19400M | -2.95400M |
| Dividends paid | -398.75200M | -391.68700M | -366.64800M | -343.57800M | 338.97M |
| Change to inventory | -2183.36800M | -665.37000M | -1116.34400M | -1621.14300M | -167.99000M |
| Change to account receivables | -2711.78600M | -1659.52500M | -930.07800M | -1628.99100M | -1241.89000M |
| Sale purchase of stock | -1180.72800M | -483.70400M | -82.15000M | -420.44900M | -674.03100M |
| Other cashflows from financing activities | -19.54000M | -48.19800M | -13.65500M | 126.06M | -16.66900M |
| Change to netincome | - | 434.10M | 244.55M | -1061.28500M | 621.95M |
| Capital expenditures | 458.36M | 496.32M | 438.22M | 369.68M | 310.22M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 874.54M | -139.66200M | 367.32M | 6664.40M | 363.38M |
| Stock based compensation | - | 93.40M | 99.59M | 74.41M | 58.87M |
| Other non cash items | 340.31M | 176.79M | -194.59000M | 4.75M | 541.59M |
| Free cash flow | 3452.97M | 2206.77M | 2228.37M | 1837.36M | 2033.80M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| COR Cencora Inc. |
-2.14 0.92% | 229.63 | 23.39 | - | - | - | ||
| MCK McKesson Corporation |
1.77 0.35% | 501.10 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
| CAH Cardinal Health Inc |
-1.77 1.61% | 108.29 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
| HSIC Henry Schein Inc |
0.55 0.78% | 70.93 | 24.12 | 14.04 | 0.74 | 2.50 | 0.95 | 13.33 |
| SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
- -% | 1.64 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
1 West First Avenue, Conshohocken, PA, United States, 19428-1800
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven H. Collis | Chairman, Pres & CEO | 1961 |
| Mr. James F. Cleary Jr. | Exec. VP & CFO | 1963 |
| Dr. Robert P. Mauch Ph.D., PharmD | Exec. VP & COO | 1967 |
| Ms. Gina K. Clark | Exec. VP and Chief Communications & Admin. Officer | 1957 |
| Mr. John G. Chou | Exec. VP and Special Advisor to the Chairman & CEO | 1956 |
| Mr. Lazarus Krikorian | Sr. VP, Chief Accounting Officer & Corp. Controller | 1965 |
| Bennett S. Murphy | Sr. VP of Investor Relations | NA |
| Ms. Kathy H. Gaddes | Exec. VP & Chief Compliance Officer | 1963 |
| Ms. Elizabeth S. Campbell | Exec. VP & Chief Legal Officer | 1975 |
| Ms. Silvana Battaglia | Exec. VP & Chief HR Officer | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...